Drug intelligence / Profile preview

Poliorix

Development stage: Approved
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**Poliorix** is GSK's trivalent, enhanced-potency inactivated poliomyelitis vaccine for active immunization against poliomyelitis. It contains inactivated poliovirus antigens representing poliovirus serotypes 1, 2, and 3 and is administered by intramuscular injection. As a non-replicating whole-virus vaccine, it induces protective humoral immunity, including poliovirus-neutralizing antibodies, without the risk of vaccine-associated paralytic poliomyelitis associated with live oral poliovirus vaccines. Clinical studies in infants and toddlers, including studies in China, Korea, and Russia, reported immunogenicity and an acceptable safety/reactogenicity profile.

Brand names: Poliorix
Other names: Inactivated poliomyelitis vaccineGSK IPVPoliomyelitis vaccine (inactivated) - Poliorix

Beyond the preview

Go deeper on Poliorix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poliorix.

Explore the full profile